Recombinant Human EGFR(Leu 25 - Ser 645) fused with Avi/His tag at C-terminal was expressed in HEK293.
The epidermal growth factor receptor (EGFR; ErbB-1; HER1 in humans) is the cell-surface receptor for members of the epidermal growth factor family (EGF-family) of extracellular protein ligands. The epidermal growth factor receptor is a member of the ErbB family of receptors, a subfamily of four closely related receptor tyrosine kinases: EGFR (ErbB-1), HER2/c-neu (ErbB-2), Her 3 (ErbB-3) and Her 4 (ErbB-4). Mutations affecting EGFR expression or activity could result in cancer. The type III EGF deletion-mutant receptor (EGFRvIII) is the most common mutation and was first identified in primary human glioblastoma tumors; EGFR gene amplification is correlated with the structural rearrangement of the gene. The EGFRvIII gene has an in-frame deletion of 801 base pairs, corresponding to exons 2–7 in the mRNA, resulting in the deletion of amino acids 30-297 in the extracellular domain and the generation of a glycine at the fusion point
Predicted N Terminal:
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization.
Has a calculated MW of 41.3 kDa. As a result of glycosylation, The protein migrates as 60-70 kDa under reducing (R) condition and 60-70 kDa under non-reducing (NR) condition on SDS-PAGE gel.
Leu 25 - Ser 645
Less than 1.0 EU per μg by the LAL method.
>95% as determined by SDS-PAGE.
For long term storage, the product should be stored at lyophilized state at -20 centigrade or lower.
Please avoid repeated freeze-thaw cycles.
No activity loss is observed after storage at:
4-8 centigrade for 12 months in lyophilized state;
-70 centigrade for 3 months under sterile conditions after reconstitution.
Reconstitute at 200 μg/mL in sterile deionized water.